

Table of Contents

Chapter 1	The Importance of Rx-to-OTC Switch to Consumer Self-Care	1
Chapter 2	Why Switch? Evaluating the Value of Switch Candidates	13
Chapter 3	What is the Rx-to-OTC switch process in the US and how does FDA regulate switches?	31
Chapter 4	Plan B Case Study: A Story of Politics Over Science	51
Chapter 5	Prilosec OTC: A Case Study	63
Chapter 6	The History and Future of Rx-to-OTC Switch for Lipid Management in the US	81
Chapter 7	Review of the Rx-to-OTC Switch of Oxytrol for Women	99
Chapter 8	Differin Gel OTC Switch: Bringing Innovation to a Well-Established Category.....	121
Chapter 9	Intranasal Corticosteroids for Allergy OTC Switch: A US Case Study	137
Chapter 10	EU and RoW Switches	161
Chapter 11	Conclusion	179
Abbreviations and Acronyms		187
Glossary of Terms.....		191
Index.....		195

Figures

Figure 1-1.	Sample Drug Facts Label	2
Figure 1-2.	Self-Care Pyramid	3
Figure 1-3.	IRI Value Study for CHPA.....	4
Figure 1-4.	Key Benefits Consumers Cite for OTC Usage	5
Figure 3-1.	Value Tree Method for Assessing Potential Benefits and Risks From a Proposed Rx-to-OTC Switch.....	33
Figure 3-2.	Lotrimin Ultra Pictogram.....	38
Figure 3-3.	Voltaren Arthritis Pain Outer Carton	39
Figure 3-4.	Voltaren Arthritis Pain Pictogram	39
Figure 3-5.	OTC Naloxone DFL Created by FDA for CONFER Pivotal Label Comprehension Study.....	40
Figure 3-6.	Enhanced DFL Warning Tested in SSS for Proposed OTC Singulair Allergy	42
Figure 5-1.	Frequency of Rx-to-OTC Switches: 1998–2002*	64
Figure 5-2.	Mechanism of Action of H2RAs and Omeprazole.....	65
Figure 5-3.	Prilosec Black Box Warning.....	66
Figure 5-4.	Percent of Subjects With Complete Prevention of Heartburn—Day 1	69

Figure 5-5.	Percent of Days with No Heartburn—Over 14 Days	70
Figure 5-6.	Percent of Subjects with 24 Hour Prevention of Heartburn—Time Course Over 14 Days (Studies 171 and 183)	72
Figure 6-1.	Schematic Outline of Mevacor OTC Consumer Behavior Studies in 1999 NDA.....	86
Figure 6-2.	The Mevacor OTC Self-Management System—2005.....	89
Figure 6-3.	Mevacor OTC Back Panel Drugs Facts Label Used in CUSTOM Study.....	90
Figure 6-4.	Mevacor OTC “5th Panel” Self-Selection Labeling Aid Used in SELECT Study.....	93
Figure 8-1.	Timeline for Rx-to-OTC Switch of Differin Gel.....	123
Figure 8-2.	Comparison of Final OTC DFL for Differin Gel to DFL for a Representative Acne Product Labeled According to the OTC Topical Acne Drug Products Monograph	124
Figure 8-3.	Results of NDAC Vote on Rx-to-OTC Switch of Differin Gel.....	133

Tables

Table 2-1.	Brands Launched via Rx-to-OTC Switch Since 2000 and Most Recent Annual US Retail Sales	15
Table 2-2.	OTC Therapeutic Categories and 2020 Annual US Retail Sales	16
Table 2-3.	Allergy Brands Launched as a Result of Rx-to-OTC Switch and Their Most Recent Annual US Retail Sales	17
Table 2-4.	Source of Volume for Recent Allergy Rx-to-OTC Switches	17
Table 2-5.	US Retail Sales by Year of Allergy Products (NSAs versus INSs).....	18
Table 2-6.	Dollar Share of Retail Sales in Drug Stores (Branded Products Versus Private Label Smoking Cessation Products)	18
Table 2-7.	PPI Brands Launched as a Result of Rx-to-OTC Switch, Peak Rx Sales and Most Recent Annual US Retail Sales	19
Table 2-8.	Reported Media Spends and Year 1 US Retail Sales for Certain Recent Rx-to-OTC Switch Brands	20
Table 2-9.	Pricing Premiums for new Waves of Innovation (Based on Class of OTC Chemical Entity) Versus the Previous Wave of Innovation.....	22
Table 2-10.	Order of Entry for Various Rx-to-OTC Switches (by Class) Versus Current Sales Rank.....	23
Table 2-11.	Advil Products Approved via new NDAs (and Year of Approval).....	23
Table 2-12.	Key Differences Between Prescription and Consumer Healthcare Business Models.....	26
Table 3-1.	Typical Rx-to-OTC Switch Studies and the Parameters They can Measure	36
Table 3-2.	Various Naming Approaches Used Over Last 10 Years	41
Table 3-3.	Primary Endpoints From Recent AUS Point to These Behavioral Measures.....	43
Table 3-4.	Elapsed Approval Times for Rx-to-OTC Switches.....	46
Table 3-5.	NDAC Advisory Committee Meetings in the Last Decade and Their Rx-to-OTC Switch Votes.....	47
Table 4-1.	Summary of Label Comprehension Results by Age.....	53
Table 4-2.	Summary of the Eight Advance Provision Studies	56
Table 4-3.	Survey Summary.....	58
Table 6-1.	Clinical Studies Supporting Merck’s 1999 NDA to Switch Lovastatin	85
Table 6-2.	BMS Pravachol Switch Program: Proposed Target OTC Population.....	86
Table 6-3.	Merck 2005 Statin Switch Program: Target OTC Population for CUSTOM Study.....	91
Table 9-1.	Examples of Lifecycle Management in Prescription Allergy Products (Pre-Switch)	139

Table 9-2.	Newer Prescription Market Brands.....	140
Table 9-3.	Over-the-Counter Allergy Market	143
Table 9-4.	Strategic Decision-Making Framework.....	146
Table 9-5.	Drug Facts Label Highlights	149
Table 9-6.	Retail Sales of the Major Switch Products for the 52 Weeks Ending July 2020	155
Table 10-1.	Example of Prescription and Nonprescription Schedules and Criteria in the UK	163
Table 10-2.	Potential Switch Supply Models	164
Table 10-3.	Comparison of Key Enablers and Barriers to Switch Across Seven Countries*	167
Table 11-1.	Typical Consumer Studies	181
Table 11-2.	Illustrative PERT/PERS Chart	182

Author Acknowledgments

On behalf of lead editor Robert Falcone and the Editorial Advisory Committee, the Regulatory Affairs Professionals Society (RAPS) would like to express appreciation to the following subject matter experts who shared their experience and knowledge by volunteering their time to contribute to the development of the first edition of *Lifecycle Management Through the Rx-to-OTC Switch: US Considerations and Perspectives to Advance Self-Care*.

Douglas Ws. Bierer, PhD

President, Douglas Bierer Consulting, LLC
US
Chapter 5

Robert Falcone, PhD, FRAPS

Senior Manager, Regulatory Affairs
Prestige Consumer Healthcare
Preface, Chapter 11

Natalie Gauld, DipPharm, MPharm, PhD, FPS

Access to Medicines Specialist
Natalie Gauld, Ltd.
New Zealand
Chapter 10

Sean Griffin, MBA

Vice President of Regulatory Affairs
Galderma
US
Chapter 8

Edwin L. Hemwall, PhD

Principal
Edwin Hemwall LLC - OTC Drug
Development Consulting Services
US
Chapter 6

Marcia D. Howard, PhD, CAE

Vice President, Regulatory and Scientific Affairs
Consumer Healthcare Products Association
(CHPA)
US
Chapter 1

Barbara A. Kochanowski, PhD

Senior Vice President, Regulatory and Scientific
Affairs
Consumer Healthcare Products Association
(CHPA)
US
Chapter 1

Susan B. Levy

Principal and Founder
Susan B. Levy Consulting, LLC
US
Chapters 2 and 3

Kristie Licata

Vice President: Rx-to-OTC Switch
Bayer Consumer Care
US
Chapter 4

Stephen G. Mann, MBBS (Lond), LRCP, MRCS, FFPM

Principal Consultant
Stephen Mann Associates Ltd.
UK
Chapter 10